Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by noclue80on Jun 27, 2022 7:21am
307 Views
Post# 34783913

PRC partners analysis

PRC partners analysis"Since the AbbVie deal was announced, Sirona Biochem has been approached by several major institutions, funds and investment banking firms. Initial meetings have already taken place and will be followed up by high-profile meetings all over the world in the coming weeks. As far as we know, additional meetings will take place in Germany, France, the U.S and Canada."

"In a recent conversation with the current CEO, Dr. Howard Verrico, we were made aware that the company has already begun the process of looking for a suitable CEO, either one from Europe or a multi-lingual candidate, to take the company to the next level. Dr. Verrico would remain with the company as president and chairman of the board. "

"The animal health market may not be as large as the anti-aging market, but a deal with a top animal pharmaceutical company could still translate to tens of millions of dollars in royalty payments."

57ea05_4dfabf8ca3aa4f9e929d16bcfcc954dd.pdf (usrfiles.com)
<< Previous
Bullboard Posts
Next >>